Navitoclax effects have been tested in combination with cisplatin and etoposide in small cell lung cancer (NCT00878449), gemcitabine (NCT00887757), paclitaxel (NCT00891605), docetaxel (NCT00888108), erlotinib (NCT01009073) and sorafenib (NCT02143401) in patients with solid cancers, dabrafinib and trametinib in BRAF mutant metastatic melanoma patients (NCT01989585), and osimertinib in EGFR positive non-small cell lung cancer patients (NCT02520778). The gene discussed is BRAF; the disease is non-small cell lung carcinoma.